These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22595153)

  • 1. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa.
    Ratjen F; Saiman L; Mayer-Hamblett N; Lands LC; Kloster M; Thompson V; Emmett P; Marshall B; Accurso F; Sagel S; Anstead M
    Chest; 2012 Nov; 142(5):1259-1266. PubMed ID: 22595153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
    Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
    JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas.
    Pittman JE; Skalland MS; Sagel SD; Ramsey BW; Mayer-Hamblett N; Retsch-Bogart GZ
    J Cyst Fibros; 2022 Nov; 21(6):946-949. PubMed ID: 35260354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic Profiling to Identify Blood Biomarkers Predictive of Response to Azithromycin in Children and Adolescents With Cystic Fibrosis.
    Dong K; Singh A; Ng RT; Sin DD; Tebbutt SJ; Ratjen F; Quon BS
    Chest; 2019 Oct; 156(4):667-673. PubMed ID: 31201785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.
    Clement A; Tamalet A; Leroux E; Ravilly S; Fauroux B; Jais JP
    Thorax; 2006 Oct; 61(10):895-902. PubMed ID: 16809416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment.
    Parnham MJ; Culić O; Eraković V; Munić V; Popović-Grle S; Barisić K; Bosnar M; Brajsa K; Cepelak I; Cuzić S; Glojnarić I; Manojlović Z; Novak-Mircetić R; Oresković K; Pavicić-Beljak V; Radosević S; Sucić M
    Eur J Pharmacol; 2005 Jul; 517(1-2):132-43. PubMed ID: 15964564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
    Saiman L; Marshall BC; Mayer-Hamblett N; Burns JL; Quittner AL; Cibene DA; Coquillette S; Fieberg AY; Accurso FJ; Campbell PW;
    JAMA; 2003 Oct; 290(13):1749-56. PubMed ID: 14519709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity.
    Sagel SD; Wagner BD; Ziady A; Kelley T; Clancy JP; Narvaez-Rivas M; Pilewski J; Joseloff E; Sha W; Zelnick L; Setchell KDR; Heltshe SL; Muhlebach MS
    J Cyst Fibros; 2020 Jul; 19(4):632-640. PubMed ID: 31870630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa.
    Saiman L; Mayer-Hamblett N; Anstead M; Lands LC; Kloster M; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
    Pediatr Pulmonol; 2012 Jul; 47(7):641-8. PubMed ID: 22684984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.
    Steinkamp G; Schmitt-Grohe S; Döring G; Staab D; Pfründer D; Beck G; Schubert R; Zielen S
    Respir Med; 2008 Nov; 102(11):1643-53. PubMed ID: 18701270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of airway and circulating inflammatory biomarkers for cystic fibrosis drug development.
    Jain R; Baines A; Khan U; Wagner BD; Sagel SD
    J Cyst Fibros; 2021 Jan; 20(1):50-56. PubMed ID: 32622665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying Long-Term Changes in Lung Function and Exacerbations after Initiation of Azithromycin in Cystic Fibrosis.
    Denis A; Touzet S; Diabaté L; Durieu I; Lemonnier L; Poupon-Bourdy S; Iwaz J; Reynaud Q; Rabilloud M
    Ann Am Thorac Soc; 2020 Feb; 17(2):195-201. PubMed ID: 31604024
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial.
    Kabra SK; Pawaiya R; Lodha R; Kapil A; Kabra M; Vani AS; Agarwal G; Shastri SS
    J Cyst Fibros; 2010 Jan; 9(1):17-23. PubMed ID: 19818694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the diagnostic accuracy of plasma markers for early diagnosis in patients suspected for acute appendicitis.
    Schellekens DH; Hulsewé KW; van Acker BA; van Bijnen AA; de Jaegere TM; Sastrowijoto SH; Buurman WA; Derikx JP
    Acad Emerg Med; 2013 Jul; 20(7):703-10. PubMed ID: 23859584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of macrolide antibiotics in patients with cystic fibrosis.
    Saiman L
    Curr Opin Pulm Med; 2004 Nov; 10(6):515-23. PubMed ID: 15510060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation.
    Horsley AR; Davies JC; Gray RD; Macleod KA; Donovan J; Aziz ZA; Bell NJ; Rainer M; Mt-Isa S; Voase N; Dewar MH; Saunders C; Gibson JS; Parra-Leiton J; Larsen MD; Jeswiet S; Soussi S; Bakar Y; Meister MG; Tyler P; Doherty A; Hansell DM; Ashby D; Hyde SC; Gill DR; Greening AP; Porteous DJ; Innes JA; Boyd AC; Griesenbach U; Cunningham S; Alton EW
    Thorax; 2013 Jun; 68(6):532-9. PubMed ID: 23396354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial.
    Equi A; Balfour-Lynn IM; Bush A; Rosenthal M
    Lancet; 2002 Sep; 360(9338):978-84. PubMed ID: 12383667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.
    Wong C; Jayaram L; Karalus N; Eaton T; Tong C; Hockey H; Milne D; Fergusson W; Tuffery C; Sexton P; Storey L; Ashton T
    Lancet; 2012 Aug; 380(9842):660-7. PubMed ID: 22901887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: a randomized, multi-center, double-blind, placebo-controlled trial.
    López-Neyra A; Suárez L; Muñoz M; de Blas A; Ruiz de Valbuena M; Garriga M; Calvo J; Ribes C; Girón Moreno R; Máiz L; González D; Bousoño C; Manzanares J; Pastor Ó; Martínez-Botas J; Del Campo R; Cantón R; Roy G; Menacho M; Arroyo D; Zamora J; Soriano JB; Lamas A
    Prostaglandins Leukot Essent Fatty Acids; 2020 Nov; 162():102186. PubMed ID: 33038833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa.
    Jones AM; Martin L; Bright-Thomas RJ; Dodd ME; McDowell A; Moffitt KL; Elborn JS; Webb AK
    Eur Respir J; 2003 Sep; 22(3):503-6. PubMed ID: 14516142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.